Search the Newsreel

IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds

IceCure Medical Ltd. has filed a post-effective amendment to register the issuance of up to 324,802 Ordinary Shares upon the exercise of outstanding warrants from a previous rights offering. The exercise includes warrants at $30.00 per share and pre-funded warrants at $0.003 per share, …

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

IceCure Medical announced two new peer-reviewed publications that support the increasing role of cryoablation in breast cancer treatment de-escalation. One review highlights ProSense®'s FDA authorization, ASBrS guidelines, and positive ICE3 trial outcomes, while the second expands cryoablation's use to axillary lymph node metastases for …

IceCure Medical Q2 2026 Earnings Call Transcript

IceCure Medical reported a 45% year-over-year revenue increase to $1.8 million for the first half of 2026, driven by higher ProSense system sales and disposable probe utilization. The company's U.S. commercial install base grew by 70% to over 30 sites following FDA clearance for …

IceCure Medical Ltd Q2 2026 Earnings Call Summary

IceCure Medical Ltd Q2 2026 Earnings Call Summary - Moby Strategic Performance and Operational Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Earnings call transcript: IceCure Medical misses Q2 2026 estimates as shares fall

IceCure Medical reported a 45% year-over-year revenue increase to $1.8 million for the first half of 2026, driven by higher ProSense system sales and disposable probe utilization. The company's U.S. commercial install base grew by 70% to over 30 sites following FDA clearance for …

IceCure Medical (Nasdaq: ICCM) lifts H1 revenue 45% but burns cash

IceCure Medical Ltd. (ICCM) reported a 45% increase in H1 2026 revenue to $1.818 million, driven by higher system and disposable probe sales. Despite this growth, the company experienced a deepened net loss of $8.775 million and negative operating cash flow, leading management to …

ICECURE MEDICAL ($ICCM) Releases Q2 2026 Earnings

IceCure First-Half 2026 Earnings: 45% Revenue Growth Comes With Wider Losses

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

IceCure Medical Ltd. announced strong financial results for the first half of 2026, reporting a 45% year-over-year revenue growth to $1.8 million, driven by increased sales of its ProSense® systems and disposable probes. The company expanded its U.S. commercial footprint by 70% and ended …

IceCure's Active U.S. Install Base Grows About 70%; Cash $12M

IceCure Medical (ICCM) names David Salton to board as independent director

IceCure Medical Ltd. (ICCM) has appointed David Salton as an independent Class II director to its Board, effective until the 2027 annual general meeting. This appointment follows the resignation of Vincent Chun Hung Chan, which the company stated was not due to any disagreements. …

IceCure Medical Shareholders Approve Special Meeting Agenda on August 6, 2026

IceCure Medical shareholders approved the sole agenda item at a Special General Meeting held on August 6, 2026, in Caesarea, Israel, after the meeting was reconvened due to a lack of quorum. The company has filed a Form 6-K with the U.S. SEC to …

Icecure Medical Ltd (ICCM) News, Articles, Events & Latest Updates

IceCure Medical (ICCM) is actively expanding its clinical studies and commercial reach for its ProSense cryoablation technology. The company recently added Adventist Health as a U.S. clinical site for its "ChoICE" study for low-risk breast cancer and will report its first-half 2026 financial results …

IceCure Medical (ICCM) holders approve agenda after adjourned meeting

IceCure Medical Ltd. shareholders approved the agenda item during a Special General Meeting held on August 6, 2026. The meeting was initially adjourned due to a lack of quorum but reconvened later the same day once sufficient shareholder presence was achieved. This information was …

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

IceCure Medical has announced that Adventist Health Glendale will be the first U.S. clinical site to enroll patients in its post-marketing "ChoICE" study for ProSense® cryoablation treatment of low-risk breast cancer. The study aims to gather real-world data on up to 400 patients across …

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

IceCure Medical Ltd. announced it will release its financial and operational results for the first half of 2026 on Wednesday, August 12, 2026, before the Nasdaq Stock Market opens. The company, which develops minimally-invasive cryoablation technology, will also host a conference call and webcast …

IceCure Medical Will Discuss Six-Month Results on Aug. 12

IceCure Medical (NASDAQ: ICCM) announced it will release its financial and operational results for the six months ended June 30, 2026, on Wednesday, August 12, 2026, before the Nasdaq Stock Market opens. The company will also host a conference call and live webcast at …

Price to book forward of IceCure Medical Ltd. – NASDAQ:ICCM

This page provides financial data for IceCure Medical Ltd. (NASDAQ: ICCM), specifically focusing on its "Price to book forward" metric. The content includes an overview of the company's financials on the Nasdaq Stock Market via TradingView, indicating that the market was closed at the …

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

IceCure Medical Ltd. has initiated its post-marketing "ChoICE" study for ProSense® cryoablation in treating low-risk breast cancer, with the West Cancer Center & Research Institute in Germantown, Tennessee, as the first U.S. clinical site. The study aims to enroll up to 400 patients across …

IceCure's tumor-freezing treatment proposed as breast surgery alternative

The Society of Interventional Oncology (SIO) has petitioned the National Comprehensive Cancer Network (NCCN) to include IceCure Medical's cryoablation treatment, ProSense®, as an alternative to breast-conserving surgery for selected low-risk, early-stage breast cancer patients. This proposal, supported by IceCure's FDA marketing authorization in October …

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

The Society of Interventional Oncology (SIO) has formally petitioned the National Comprehensive Cancer Network (NCCN) to include percutaneous cryoablation in breast cancer treatment guidelines, specifically for low-risk, early-stage cases. This petition, which seeks to expand eligibility to patients aged 50-69 who are poor surgical …

Icecure Medical Ltd (ICCM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Icecure Medical Ltd (ICCM), highlighting its current risk score, industry ranking, and beta value of 1.53. It details various risk metrics including VaR, maximum drawdown, volatility, Sharpe Ratio, and daily returns over different periods. The assessment also …

Icecure Medical Ltd (ICCM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Icecure Medical Ltd's (ICCM) shareholder structure, listing major individual shareholders and their respective proportions. It also categorizes shareholders by type, such as individual investors, investment advisors, and hedge funds, alongside institutional shareholding data over recent quarters. The …

Icecure Medical Ltd (ICCM) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a dividend and stock split history for Icecure Medical Ltd (ICCM). It indicates that the company has not distributed any dividends over the past five years. There is one recorded stock split event, a 30-to-1 merger, scheduled for June 02, 2026.

IceCure Medical launches U.S. post-marketing study for ProSense® cryoablation in low-risk breast cancer.

IceCure Medical has initiated the U.S. post-marketing "ChoICE Study" for its ProSense® cryoablation system, targeting low-risk breast cancer. West Cancer Center & Research Institute is the first clinical site, aiming to enroll up to 400 patients across 30 locations. This study intends to gather …

Icecure Medical Ltd (ICCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Icecure Medical Ltd (ICCM), focusing on its regional revenue contributions. As of April 6, the company's revenue distribution shows "Other" regions contributing 57.32%, followed by the United States at 26.87% and Japan at 8.35%. No data for …

Icecure Medical Ltd|Price:3.080|Chg%:-0.150

Icecure Medical Ltd (ICCM) shows relatively healthy fundamentals and significant growth potential, despite recent weak market performance. The company's valuation is considered fairly valued within the Healthcare Equipment & Supplies industry, with high institutional ownership and analyst ratings suggesting a "Buy" with an upside …

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

IceCure Medical Ltd. has expanded its U.S. sales and marketing teams, adding new professionals in key territories and more clinical support. This expansion addresses the surging demand for its ProSense® cryoablation technology, particularly for breast cancer, following FDA marketing authorization and a 70% growth …